<DOC>
	<DOCNO>NCT00849667</DOCNO>
	<brief_summary>This research do find Carboplatin Taxane work well alone give experimental drug call MORAb-003 ( farletuzumab ) subject first platinum sensitive relapse ovarian cancer .</brief_summary>
	<brief_title>Efficacy Safety MORAb-003 Subjects With Platinum-sensitive Ovarian Cancer First Relapse</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>A histologically cytologically confirm diagnosis nonmucinous epithelial ovarian cancer include primary peritoneal fallopian tube malignancy Must measurable disease CT MRI scan Must relapse radiologically randomization date within ≥6 &lt; 24 month completion firstline platinum chemotherapy Have treat debulking surgery firstline platinum taxane base chemotherapy . Prior bevacizumbab maintenance allow . The last dose bevacizumab must least 30 day study Day 1 . No cytotoxic maintenance therapy ( e.g . taxane ) cancer vaccine therapy allow . Must candidate carboplatin taxane therapy Neurologic function : neuropathy ( sensory motor ) ≤CTCAE Grade 1 Subjects never respond firstline platinumbased therapy whose first relapse occur &lt; 6 month &gt; 24 month last platinum therapy Subjects receive therapy treat ovarian cancer since relapse Known central nervous system ( CNS ) tumor involvement Evidence active invasive malignancy require treatment past 5 year Known allergic reaction prior monoclonal antibody therapy document HAHA Previous treatment MORAb003 ( farletuzumab ) Clinical contraindication use taxane</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>relapsed ovarian cancer</keyword>
	<keyword>Platinum-sensitive Ovarian Cancer</keyword>
</DOC>